GT Biopharma Reports Improved Quarterly Losses

Gt Biopharma, Inc. ( (GTBP) ) has released its Q1 earnings. Here is a breakdown of the information Gt Biopharma, Inc. presented to its investors.

GT Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel immune-oncology products using its proprietary Tri-specific Killer Engager (TriKE®) and Tetra-specific Killer Engager platforms to enhance the cancer-killing abilities of natural killer cells.

GT Biopharma’s latest earnings report for the quarter ending March 31, 2025, highlights a continued focus on research and development, despite operating losses. The company remains committed to advancing its proprietary platforms and product candidates.

The company reported no revenues for the quarter, with a net loss of $776,000, a significant improvement from the $2.3 million loss in the same period last year. Operating expenses were primarily driven by research and development costs, which increased to $1.1 million, while selling, general, and administrative expenses decreased significantly to $833,000. The company also benefited from a $998,000 gain on the settlement of vendor payables.

GT Biopharma’s financial position shows a reduction in cash and cash equivalents to $2.4 million from $4 million at the end of 2024, reflecting cash used in operations. The company continues to face challenges in securing additional financing to support its operations and product development efforts.

Looking ahead, GT Biopharma’s management remains focused on advancing its clinical programs and exploring strategic collaborations to enhance its financial position and support the development of its innovative cancer therapies.